DIABETIC MACULAR EDEMA (DME)
Clinical trials for DIABETIC MACULAR EDEMA (DME) explained in plain language.
Never miss a new study
Get alerted when new DIABETIC MACULAR EDEMA (DME) trials appear
Sign up with your email to follow new studies for DIABETIC MACULAR EDEMA (DME), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye injection aims to restore vision in diabetes patients
Disease control Recruiting nowThis study tests a new medicine called BAT5906 against an approved drug (Lucentis) for diabetic macular edema, a condition that causes vision loss in people with diabetes. About 406 adults aged 18 to 80 with diabetes and swelling in the center of the eye will receive injections i…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
Gene therapy injection could ease diabetic eye swelling
Disease control Recruiting nowThis early-stage study tests a gene therapy called LX111 for diabetic macular edema, a condition that causes vision loss due to swelling in the eye. About 32 adults with diabetes will receive a single injection into the eye. The goal is to see if it is safe and can reduce swellin…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New eye implant could slash injections for diabetes-related vision loss
Disease control Recruiting nowThis study tests an eye implant called EYP-1901 that slowly releases medication to treat diabetic macular edema, a condition that causes vision loss in people with diabetes. About 240 adults with this eye condition will receive either the implant or standard aflibercept injection…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New eye drug could cut injection frequency for diabetic vision loss
Disease control Recruiting nowThis phase 3 study tests whether a new drug, EYP-1901, works as well as the standard treatment aflibercept for diabetic macular edema, a condition that causes vision loss. About 240 adults with DME will receive either EYP-1901 or aflibercept injections. The goal is to see if EYP-…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Eye scans may predict which diabetes drug works best
Knowledge-focused Recruiting nowThis study looks at 100 adults with diabetic retinopathy to see if eye scans can predict early response to two different drugs (faricimab and biosimilar ranibizumab). Participants receive three injections and undergo imaging and blood tests. The goal is to find biomarkers that he…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: NA • Sponsor: Osijek University Hospital • Aim: Knowledge-focused
Last updated May 13, 2026 16:02 UTC